Rapid Assay for Sick Children with Acute Lung infection Study (RASCALS): diagnostic cohort study protocol.
Kean, Iain Robert Louis
Curran, Martin D
Bartholdson Scott, Josefin
MetadataShow full item record
Clark, J., Kean, I. R. L., Curran, M. D., Khokhar, F., White, D., Daubney, E., Conway Morris, A., et al. (2021). Rapid Assay for Sick Children with Acute Lung infection Study (RASCALS): diagnostic cohort study protocol.. BMJ Open, 11 (11. ARTN e056197), e056197. https://doi.org/10.1136/bmjopen-2021-056197
INTRODUCTION: Lower respiratory tract infection (LRTI) is the most commonly treated infection in critically ill children. Pathogens are infrequently identified on routine respiratory culture, and this is a time-consuming process. A syndromic approach to rapid molecular testing that includes a wide range of bacterial and fungal targets has the potential to aid clinical decision making and reduce unnecessary broad spectrum antimicrobial prescribing. Here, we describe a single-centre prospective cohort study investigating the use of a 52-pathogen TaqMan array card (TAC) for LRTI in the paediatric intensive care unit (PICU). METHODS AND ANALYSIS: Critically ill children with suspected LRTI will be enrolled to this 100 patient single-centre prospective observational study in a PICU in the East of England. Samples will be obtained via routine non-bronchoscopic bronchoalveolar lavage which will be sent for standard microbiology culture in addition to TAC. A blood draw will be obtained via any existing vascular access device. The primary outcomes of the study will be (1) concordance of TAC result with routine culture and 16S rRNA gene sequencing and (2) time of diagnostic result from TAC versus routine culture. Secondary outcomes will include impact of the test on total antimicrobial prescriptions, a description of the inflammatory profile of the lung and blood in response to pneumonia and a description of the clinical experience of medical and nursing staff using TAC. ETHICS AND DISSEMINATION: This study has been approved by the Yorkshire and the Humber-Bradford Leeds Research Ethics Committee (REC reference 20/YH/0089). Informed consent will be obtained from all participants. Results will be published in peer-reviewed publications and international conferences. TRIAL REGISTRATION NUMBER: NCT04233268.
molecular diagnostics, paediatric intensive & critical care, respiratory infections, Child, Cohort Studies, Humans, Lung, Observational Studies as Topic, Pneumonia, Prospective Studies, RNA, Ribosomal, 16S
Addenbrooke's Charitable Trust (ACT) (900240)
Action Medical Research (GN2903)
External DOI: https://doi.org/10.1136/bmjopen-2021-056197
This record's URL: https://www.repository.cam.ac.uk/handle/1810/332599
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/